NanoViricides (NYSE:NNVC – Get Free Report) was downgraded by analysts at StockNews.com from a “hold” rating to a “sell” rating in a research report issued on Wednesday.
NanoViricides Stock Performance
Shares of NYSE NNVC traded up $0.20 during midday trading on Wednesday, hitting $2.26. 535,293 shares of the stock traded hands, compared to its average volume of 164,080. The firm has a market capitalization of $26.69 million, a P/E ratio of -2.76 and a beta of 0.97. NanoViricides has a one year low of $1.00 and a one year high of $3.59. The firm has a 50-day moving average of $2.08 and a two-hundred day moving average of $1.49.
NanoViricides (NYSE:NNVC – Get Free Report) last posted its earnings results on Wednesday, May 15th. The company reported ($0.16) earnings per share for the quarter.
About NanoViricides
NanoViricides, Inc, a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company's product portfolio includes NV-CoV-2, nanoviricide drug which is in phase 1a/1b clinical trails for the treatment of Covid; and NV-CoV-2 Oral Syrup, and NV-CoV-2 Oral Gummies, a semi-solid fixed-dose form which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric cases.
See Also
- Five stocks we like better than NanoViricides
- How to Calculate Options Profits
- Real Estate Stock Signals a Boom in Manufacturing Activity
- Business Services Stocks Investing
- This Medical Giant’s Stock Rebounds: A 15% Upside Is the Minimum
- What is the Nikkei 225 index?
- Financial Giant’s Shares Soar on EPS Beat and Record Asset Levels
Receive News & Ratings for NanoViricides Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NanoViricides and related companies with MarketBeat.com's FREE daily email newsletter.
